As with navitoclax, a possible lead-in dose of BCLXL inhibitor may lower the risk of severe thrombocytopenia, but clinical efficacy might also be compromised because suboptimal BCLXL inhibition during the lead-in might facilitate the development of tumor cell tolerance. Here, BCL2L1 is linked to Thrombocytopenia.